2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Crit...
Jan 16, 2026DOI: 10.1093/cid/ciaf424Journal ArticleCID
Written by: Adarsh BhimrajYngve Falck-YtterLindsey R BadenRoger BedimoKelly CawcuttVincent Chi-Chung ChengKara W ChewKathleen ChiotosEric S DaarAmy L DzierbaDavid V GliddenErica J HardySteven JohnsonArthur Y KimJonathan Z LiChristine MacBrayneGreg S MartinNandita NadigMari M NakamuraJeffrey C PearsonLaura RileyRobert W ShaferShmuel ShohamAmy Hirsch ShumakerPablo TebasPhyllis C TienJennifer LovelessRebecca L MorganRajesh T Gandhi
Find these authors on Roon
AK
Dr. Arthur Kim
HIV/AIDS Medicine · MGH
SS
Dr. Shmuel Shoham
Transplant/Immunocompromised States · Johns Hopkins
Summary
As the first part of several focused updates to the clinical practice guideline on the treatment and management of COVID-19 in adults, children, and pregnant people, developed by the Infectious Diseases Society of America, the panel presents four new recommendations. These recommendations include pre-exposure prophylaxis for immunocompromised persons and treatment of severe or critical COVID-19. The panel's recommendations are based upon evidence derived from systematic literature reviews and adhere to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach.